Terns Pharmaceuticals (NASDAQ:TERN) has announced the appointment of Andrew Gengos as chief financial officer (CFO), effective immediately.
Mr. Gengos brings 25 years of leadership experience in life sciences and biotechnology. Prior to joining Terns, he served as CFO of Athira Pharma. Mr. Gengos was also chief business officer at Cyteir Therapeutics where he oversaw the finance team that took the company public. During his roles as CEO at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, he delivered strategic and financial leadership across multiple therapeutic areas, including oncology and neurodegenerative disease. Additionally, Mr. Gengos was VP of strategy and corporate development at Amgen. Early in his career, he held roles at McKinsey & Co., as well as Morgan Stanley.
In a statement, Amy Burroughs, CEO of Terns, said, “We are delighted to have Andrew join the Terns’ team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew’s contributions as we continue to advance our mission to transform patients’ lives through the development of new medicines that have a valuable, enduring impact on human health.”
Mr. Gengos commented, “I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards compelling clinical readouts later this year. I look forward to working with the talented Terns’ leadership team to build on the company’s strong financial foundation and drive continued success in bringing new treatment options to patients battling serious diseases, including oncology and obesity.”
